It is well recognized that obesity is a big problem and it can induce large economic burden. Obesity affects about 40% people in the America alone and obesity also is the worldwide problem, with about 400 million obese adults. Moreover, another problem of obesity is the increasing prevalence of overweight children. Though bariatric surgery remains the gold treatment modality in the obesity treatment, endoluminal approaches may have the meaningful role for weight control. Endoscopists should have a role in the management of obesity because endoluminal therapies demonstrate their safety and efficacy over the coming years. Endoluminal therapies can be summarized by above methods: space occupying, malabsorption method, and reduction of gastric volume. In this review, we will introduce various restrictive endoscopic procedures in obesity treatment. Clin Endosc 2017;50:17-20
INTRODUCTION
In spite of the low complication rates related to laparoscopic bariatrics, there is an increasing attention in endoluminal and/or transgastric instruments for weight loss procedures.
Interest in endoluminal treatments for the obese has been present for many years. The first breakthrough in endoluminal therapy has been the intragastric balloon (IGB), currently the Orbera balloon, but previously referred to as the Bioenterics intragastric balloon (BIB). The IGB provides a short term supplemental therapy. Nowadays, several companies are developing various balloon devices for obesity treatment. This summary will highlight the various developments on IGB.
RESTRICTIVE ENDOSCOPIC PROCEDURES

Intragastric ballooning
Various space-occupying devices are used in the world. Nowadays, they are intended to act as a bridging therapy to bariatric surgery by decreasing the patients' body mass index (BMI) with the using of a balloon in the gastric space. [1] [2] [3] [4] [5] [6] The first clinically reliable balloon received contrast enhancement (CE) mark in 1998 and has become the world leader in intraluminal weight loss devices. The Orbera balloon also known as the BIB has been placed in over 250,000 patients. This balloon was approved by the Food and Drug Administration (FDA) for US use in 2015.
The balloon is inserted into the stomach through the oral cavity and esophagus using an endoscopic procedure. During procedure, the patient is under sedation. After balloon insertion, balloon is filled with methylene blue mixed saline water, therefore, it expands into a spherical shape balloon. The balloon can be filled with various amounts of saline (from 400 to 700 cc) to best match the patient' s gastric structure. The intra-gastric balloon should be removed approximately after 6 months.
The BIB™ System is currently being tested (Allergan, Irvine, CA, USA). Fig. 1 shows this System. This System is a saline-filled balloon that is placed into the gastric space with using gastroscopy. There was large scaled data about the BIB System. Total about 2,500 patients were enrolled with a mean BMI of 44.4. This system was introduced to these patients. Improvement of BMI and obesity related diseases were evaluated. After 6 months, mean BMI and excess body weight loss (EWL) were 35.4±11.8 and 33.9±18.9.
7 Obesity-related parameters such as fasting low density lipoprotein cholesterol, blood glucose, triglyceride, and blood pressure was significantly improved. HbA1c level was significantly decreased in 87.2% among 488 diabetes patients. There were two mortality cases associated with balloon placement and these patients had a history of gastric surgery. The rate of complication was about 2.8%. BIB System within a multidisciplinary weight management program is a relatively short term effective procedure for weight control, but it is not possible to certify its potential to maintain the weight for a long time. Fulfillium (Napa, CA, USA) is developing a balloon having multiple compartments. This system has failure detection systems to enable early detection, therefore, endoscopist can remove a leaking balloon prior to collapse, and avoid passage of it to the duodenum (Fig. 2) . Based on previous experience with balloon technology, this method is appropriate; however, it is the safety profile that contributes to its limited use.
Other available balloons are the Reshape Balloon, which can provide similar weight loss as the Orbera. Unlike the Orbera, these balloons are in a fixed position within the stomach and as a result there is 26% incidence of significant ulceration along with a 2% incidence of spontaneous balloon deflation. ReShape Medical (San Clemente, CA, USA) performs to a prospective, non-randomized, multicenter study designed to implant up to 20 CE-marked ReShape™ Balloons in twenty patients with BMI between 30 and 40.
8 Enrolled patients will be followed after videotaped endoscopic placement of the 900 cc dual balloon design at 180 days and again 210 days for an additional endoscopy documenting post-removal mucosa. From the clinical view, the IGB can cause three dominant intolerance symptoms: nausea (vomiting), reflux and abdominal pain, all of which are prophylactically treated before and after balloon placement to avoid "early removal". At present, intolerance symptoms which can lead to early removal occur in 26% of patients. Using only the large Orbera data, the incidence of ulceration, deflation with migration, and small bowel obstruction are negligible. 2 . This system is a gastric balloon with multiple compartments. This system has failure detection systems to enable early detection.
Fig. 3. This system is TransPyloric Shuttle (TPS)
. This system restricts food ingestion with repeatedly blocking of the pylorus.
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Other restrictive methods for obesity treatment BAROnova Therapeutics (Goleta, CA, USA) is making the TransPyloric Shuttle™ (TPS) (Fig. 3) . This system restricts food ingestion with repeatedly blocking of the pylorus. And therefore, it makes food to increase the contact time within stomach. 9 TPS can be performed with endoscopy under sedation. It does not need any fixation to anchor this device. Pilot studies have proven safety and initial efficacy of the product with significant EWL at three months. BaroSense (Redwood City, CA, USA) has developed the Trans-oral Endoscopic Restrictive Implant System™ (TERIS) (Fig. 4) . This system is located in stomach cardia area, therefore, this system can induce early and prolonged satiety. 10 This system is currently enrolling patients in a phase 1 trial with a secondary objective to perform a preliminary evaluation of the efficacy to guide their pivotal trial. EndoSphere (Redwood City, CA, USA) has developed SatiSphere™, an endoscopically placed device increasing the food contact time (Fig. 5) . Its length is about 20-25 cm, this system is self-anchored in the distal stomach or proximal duodenum, and, it makes increased hormonal signaling, thereby causing early satiety and downregulation of glucose production. Ultimately, this system would be removed between 6 and 18 months and act as an adjunct to diet and exercise. A small study of 11 patients was performed and showed 12% EWL at 1 month without any adverse events.
CONCLUSION
Endoscopic endoluminal treatment of obesity can be a noninvasive, cost-effective, and relatively safer option than bariatric surgery. However, there are many debates according to the long efficacy, economic feasibility and durability of these procedures. Anyway, role of therapeutic endoscopist is very important in the obesity management in aspects of the primary modality for managing complications that occur after bariatric surgery as well as endoscopic endoluminal treatment of obesity. In the near future, role of gastroenterologists will be more important in the management of obesity and its related problems.
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